For Biotech Founders
The first 2-3 years of a biotech startup's journey are crucial. Some mistakes are expensive to fix and can be avoided with planning based on foresight and real-world experience.
Make impactful decisions while preserving precious capital. Our consultancy services are designed to provide comprehensive support, ensuring you extend your runway for success. Having been in your position and part of successful exits, we bring a unique perspective and invaluable experience to your team and offer options to share the risk with you.
Dedicated packages for early-stage biotech
Runway & Budget plan & review
Early foundations for successful CMC
Pivot / Recovery mode
Preparation for future funding rounds
Comprehensive CDMO selection & management
Light-touch Project Management for startups
Lab startup / move / expansion
IT setup for Biotech startups
We offer an integrated, cross-functional team with deep-rooted expertise to foster holistic decisions. Our invested team shares risk as partners through a hybrid financing model, including sweat equity and success milestones (optional). Additionally, we tap into our network of world class experts, whom we have personally worked with and trust, to bring in the expertise you need at the time and frequency required.
Partner with us to leverage our expertise and achieve your strategic objectives with confidence.
Preparation for Funding Rounds
Early Foundations for Successful CMC
Clinical Development & Operations Roadmap
Pivot / Recovery Mode
Runway & Budget Plan & Review
Light-touch Project Management for Startups
Lab Startup / Move / Expansion
Our founding team
We built our experience in prestigious companies to include CRISPR, GammaDelta, Oxford Biomedica, Lonza, NightStar, Takeda and Biogen. We are supported by a team of trusted experts and former colleagues to bring CMC, Programme, Regulatory, Clinical, IT and Lab support.
How can we help you meet your goals?
Evi Dimitriadou
Evi’s career, which spans near two decades, started with successfully developing platforms for difficult-to-manufacture biologics. Her passion for innovation led her into technology evaluation and development of a personalised medicine platform. Over the last 10 years, Evi has leveraged her scientific background in Programme and Portfolio management in biotech startup, global CDMO and Big Pharma environments, each requiring tailored approaches. She helps biotech companies make holistic and healthy decisions and make breakthrough therapies possible through solid planning and execution.
Mardon McFarlane
Mardon brings almost two decades of experience in the biotech industry having biologics (recombinant proteins, antibodies) and cell and gene therapy (viral vectors, CAR Ts and CRISPR mediated therapies) experience. He has enjoyed developing and leading process development and manufacturing activities for many modalities. Having worked on more than 20 IND/CTA submissions and two first-in-class BLA candidates, Mardon has a deep understanding of the current CMC challenges and opportunities and is passionate about translating excellent science into accessible therapies.
